Staci N. Keller

1.0k total citations
15 papers, 844 citations indexed

About

Staci N. Keller is a scholar working on Molecular Biology, Cell Biology and Immunology. According to data from OpenAlex, Staci N. Keller has authored 15 papers receiving a total of 844 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 3 papers in Cell Biology and 3 papers in Immunology. Recurrent topics in Staci N. Keller's work include Sphingolipid Metabolism and Signaling (9 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Protein Kinase Regulation and GTPase Signaling (2 papers). Staci N. Keller is often cited by papers focused on Sphingolipid Metabolism and Signaling (9 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Protein Kinase Regulation and GTPase Signaling (2 papers). Staci N. Keller collaborates with scholars based in United States, India and Italy. Staci N. Keller's co-authors include Charles D. Smith, Yan Zhuang, John J. Upson, Kevin J. French, Lynn W. Maines, Jong K. Yun, Zuping Xia, Cecelia L. Green, Peng Gao and Wenxue Wang and has published in prestigious journals such as International Journal of Molecular Sciences, Journal of Pharmacology and Experimental Therapeutics and Tetrahedron.

In The Last Decade

Staci N. Keller

14 papers receiving 814 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Staci N. Keller United States 10 742 290 102 91 76 15 844
Taekyoung Kwak United States 16 399 0.5× 144 0.5× 182 1.8× 163 1.8× 66 0.9× 21 685
Nicolas Maestre France 11 658 0.9× 138 0.5× 72 0.7× 198 2.2× 37 0.5× 13 774
Jo Waaler Norway 17 981 1.3× 156 0.5× 108 1.1× 303 3.3× 46 0.6× 22 1.2k
Rudi Baron United States 19 753 1.0× 287 1.0× 71 0.7× 224 2.5× 178 2.3× 27 1.1k
Heidi R. Hope United States 9 366 0.5× 151 0.5× 108 1.1× 56 0.6× 39 0.5× 13 528
Xavier Bisteau Belgium 17 654 0.9× 221 0.8× 51 0.5× 282 3.1× 28 0.4× 28 1.0k
J P Jaffrézou France 12 652 0.9× 115 0.4× 119 1.2× 220 2.4× 43 0.6× 20 865
Patricia Ambroziak United States 8 550 0.7× 132 0.5× 66 0.6× 127 1.4× 36 0.5× 8 706
Caroline M. Woolston United Kingdom 14 446 0.6× 145 0.5× 113 1.1× 101 1.1× 32 0.4× 16 671
Fabrizio Villa United Kingdom 18 1.1k 1.4× 454 1.6× 134 1.3× 236 2.6× 189 2.5× 20 1.2k

Countries citing papers authored by Staci N. Keller

Since Specialization
Citations

This map shows the geographic impact of Staci N. Keller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Staci N. Keller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Staci N. Keller more than expected).

Fields of papers citing papers by Staci N. Keller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Staci N. Keller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Staci N. Keller. The network helps show where Staci N. Keller may publish in the future.

Co-authorship network of co-authors of Staci N. Keller

This figure shows the co-authorship network connecting the top 25 collaborators of Staci N. Keller. A scholar is included among the top collaborators of Staci N. Keller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Staci N. Keller. Staci N. Keller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Maines, Lynn W., Staci N. Keller, Charles D. Smith, & Charles D. Smith. (2025). Opaganib Promotes Weight Loss and Suppresses High-Fat Diet-Induced Obesity and Glucose Intolerance. Diabetes Metabolic Syndrome and Obesity. Volume 18. 969–983.
2.
Maines, Lynn W., et al.. (2024). Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma Cells. Cancers. 16(9). 1779–1779. 1 indexed citations
3.
Maines, Lynn W., Staci N. Keller, & Charles D. Smith. (2023). Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy. International Journal of Molecular Sciences. 24(23). 16901–16901. 12 indexed citations
4.
Maines, Lynn W., et al.. (2022). The Sphingosine Kinase 2 Inhibitor Opaganib Protects Against Acute Kidney Injury in Mice. International Journal of Nephrology and Renovascular Disease. Volume 15. 323–334. 3 indexed citations
5.
Smith, Charles D., et al.. (2022). Recent Progress in the Development of Opaganib for the Treatment of Covid-19. Drug Design Development and Therapy. Volume 16. 2199–2211. 15 indexed citations
6.
Maines, Lynn W., Randy S. Schrecengost, Yan Zhuang, et al.. (2022). Opaganib Protects against Radiation Toxicity: Implications for Homeland Security and Antitumor Radiotherapy. International Journal of Molecular Sciences. 23(21). 13191–13191. 3 indexed citations
7.
Schrecengost, Randy S., Cecelia L. Green, Yan Zhuang, et al.. (2018). In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183. Journal of Pharmacology and Experimental Therapeutics. 365(1). 107–116. 12 indexed citations
8.
Smith, Christopher L., et al.. (2016). Antitumor and anti-inflammatory effects of the sphingosine kinase-2 inhibitor ABC294640 in combination with radiation. European Journal of Cancer. 69. S61–S61. 2 indexed citations
9.
Schrecengost, Randy S., Staci N. Keller, Matthew J. Schiewer, Karen E. Knudsen, & Charles D. Smith. (2015). Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Molecular Cancer Research. 13(12). 1591–1601. 41 indexed citations
10.
Gangjee, Aleem, Ojas A. Namjoshi, Staci N. Keller, & Charles D. Smith. (2011). 2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance. Bioorganic & Medicinal Chemistry. 19(14). 4355–4365. 10 indexed citations
11.
French, Kevin J., Yan Zhuang, Lynn W. Maines, et al.. (2010). Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2. Journal of Pharmacology and Experimental Therapeutics. 333(1). 129–139. 270 indexed citations
12.
D’Auria, Maria Valeria, Simona De Marino, Valentina Sepe, et al.. (2008). Jaspamides M–P: new tryptophan modified jaspamide derivatives from the sponge Jaspis splendans. Tetrahedron. 65(1). 51–56. 34 indexed citations
13.
Maines, Lynn W., Leo R. Fitzpatrick, Kevin J. French, et al.. (2007). Suppression of Ulcerative Colitis in Mice by Orally Available Inhibitors of Sphingosine Kinase. Digestive Diseases and Sciences. 53(4). 997–1012. 153 indexed citations
14.
French, Kevin J., John J. Upson, Staci N. Keller, et al.. (2006). Antitumor Activity of Sphingosine Kinase Inhibitors. Journal of Pharmacology and Experimental Therapeutics. 318(2). 596–603. 208 indexed citations
15.
Ducker, Charles, et al.. (2006). Discovery and characterization of inhibitors of human palmitoyl acyltransferases. Molecular Cancer Therapeutics. 5(7). 1647–1659. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026